Round window perfusion dynamics: Implications for intracochlear therapy

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 18, Issue 5, 2010, Pages 377-385

  Bowe, Sarah N ^a   Jacob, Abraham ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

drug delivery; inner ear; intracochlear; intratympanic; round window

Indexed keywords

BECLOMETASONE; BIOPOLYMER; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; DEXAMETHASONE; DEXATOPIC; GELATIN; GENTAMICIN; GLUTARALDEHYDE; HYALURONIC ACID; METHYLPREDNISOLONE; NANOPARTICLE; PLACEBO; PREDNISONE; STREPTOMYCIN;

CATHETERIZATION; CLINICAL TRIAL; COCHLEA FENESTRA; COCHLEA PROSTHESIS; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DYNAMICS; HUMAN; HYDROGEL; IDIOPATHIC DISEASE; MENIERE DISEASE; NONHUMAN; OSMOTIC MINIPUMP; PERCEPTION DEAFNESS; PERFUSION; PRIORITY JOURNAL; REVIEW; TINNITUS; TYMPANOSTOMY TUBE; VERTIGO;

CATHETERIZATION; COCHLEA; DRUG DELIVERY SYSTEMS; HUMANS; LABYRINTH DISEASES; ROUND WINDOW, EAR; TYMPANIC MEMBRANE;

EID: 77957776869     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32833d30f0     Document Type: Review

References (92)

1. Fowler EP. Streptomycin treatment of vertigo. Trans Am Acad Ophthalmol Otolaryngol 1948; 52:293-301.
2. Berryhill WE, Graham MD. Chemical and physical labyrinthectomy for Me-niere's disease. Otolaryngol Clin North Am 2002; 35:675-682.
3. Coelho DH, Lalwani AK. Medical management of Meniere's disease. Lar-yngoscope 2008; 118:1099-1108.
4. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol 1980; 106:772-776.
5. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss. I. A systemic review. Arch Otolaryngol Head Neck Surg 2007; 133:573-581.
6. Juhn S, Rybak L. Labyrinthine barriers and cochlear homeostasis. Acta Otolaryngol 1981; 91:529-534.
7. Juhn S. Barrier system in the inner ear. Acta Otolaryngol Suppl 1988; 458:79-83.
8. Juhn S, Hamaguchi Y, Goycoolea M. Review of round window membrane permeability: a review. Acta Otolaryngol Suppl 1989; 457:43-48. (Pubitemid 19079194)
9. Goycoolea MV, Lundman L. Round window membrane. Structure function and permeability: a review. Microsc Res Tech 1997; 36:201-211.
10. Goycoolea MV. Clinical aspects of round window membrane permeability undernormal and pathologicalconditions. Acta Otolaryngol 2001; 121:437-447.
11. Silverstein H, Rowan PT, Olds MJ, et al. Inner ear perfusion and the role of round window patency. Am J Otol 1997; 18:586-589.
12. Alzamil KS, Linthicum FH. Extraneous round window membranes and plugs: possible effect on intratympanic therapy. Ann Otol Rhinol Laryngol 2000; 109:30-32.
13. Crane BT, Minor LB, Della Santina CC, et al. Middle earexploration in patients with Meniere's disease who have failed outpatient intratympanic gentamicin therapy. Otol Neurotol 2009; 30:619-624.
14. Salt AN, Ma Y. Quantification of solute entry into cochlear perilymph through the round window membrane. Hear Res 2001; 154:88-97.
15. Salt AN. Simulation of methods for drug delivery to the cochlear fluids. Adv Otorhinolaryngol 2002; 59:140-148.
16. Plontke SKR, Wood AW, Salt AN. Analysis of gentamicin kinetics in fluids of the inner ear with round window administration. Otol Neurotol 2002; 23:967-974.
17. Plontke SKR, Salt AN. Quantitative interpretation of corticosteroid pharma-cokinetics in inner fluids using computer simulations. Hear Res 2003; 182:34-42.
18. Plontke SK, Siedow N, Wegener R, et al. Cochlear pharmacokinetics with local innereardrug deliveryusing athree-dimensionalfinite-elementcomputer model. Audiol Neurotol 2007; 12:37-48.
19. Banerjee A, Lorne SP. The biology of intratympanic drug administration and pharmacodynamics of round window drug absorption. Otolaryngol Clin North Am 2004; 37:1035-1051.
20. Salt AN, Plontke SK. Local innerear drug delivery and pharmacokinetics. Drug Discov Today 2005; 10:1299-1306.
21. Schuknecht HF. Ablation therapy for relief of Meniere's disease. Laryngo-scope 1956; 66:859-870.
22. Beck C, Schmidt CL. 10 years experience with intratympanically applied streptomycin (gentamicin) in the therapy of Morbus Meniere. Arch Otorhino-laryngol 1978; 221:149-152.
23. Nedzelski JM, Bryce GE, Pfleiderer AG. Treatment of Meniere's disease with topical gentamicin: a preliminary report. J Otolaryngol 1992; 21:95-101.
24. Nedzelski JM, Schessel DA, Bryce GE, et al. Chemical labyrinthectomy: local application of gentamicinforthetreatment of unilateral Meniere'sdisease. Am J Otol 1992; 13:18-22
25. Minor LB. Intratympanic gentamicin for control ofvertigo in Meniere's disease: vestibularsigns that specify completion of therapy. Am J Otol 1999; 20:209-219.
26. Chia SH, Gamst AC, Anderson JP, et al. Intratympanic gentamicin therapy for Meniere's disease: a meta-analysis. Otol Neurotol 2004; 25:544-552.
27. Postema RJ, Kingma CM, Wit HP, et al. Intratympanic gentamicin therapy for control of vertigo in unilateral Meniere's disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol 2008; 128: 876-880.
28. Hsieh LC, Lin HC, Tsai HT, et al. High-dose intratympanic gentamicin instillations for treatment of Meniere's disease: long term results. Acta Otolaryngol 2009; 129:1420-1424.
29. Kyrodimos E, Aidonis I, Sismanis A, et al. Hearing results following intratym-panic gentamicin perfusion for Meniere's disease. J Laryngol Otol 2009; 123:379-382.
30. Derebery MJ, Fisher LM, Berliner K, et al. Outcomes of endolymphatic shunt surgery for Meniere's disease: comparison with intratympanic gentamicin on vertigo control and hearing loss. Otol Neurotol 2010; 31:649-655.
31. Herraiz C, Plaza G, Aparicio JM, et al. Transtympanic steroids for Meniere's disease. Otol Neurotol 2010; 31:162-167.
32. Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol 2008; 29:453-460.
33. Ahn JH, Yoo MH, Yoon TH, et al. Can intratympanicdexamethasoneadded to systemic steroids improve hearing outcome in patients with sudden deaf-ness? Laryngoscope 2008; 188:279-282.
34. Han C-S, Park J-R, Boo S-H, et al. Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes. Oto-laryngol Head Neck Surg 2009; 141:572-578.
35. Hong SM, Park CH, Lee JH. Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngol Head Neck Surg 2009; 141:579-583.
36. Kara E, Cetik F, Tarkan O, et al. Modified intratympanictreatmentforidiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 2010; 267:701-707.
37. Topak M, Sahin-Yilmaz A, Ozdoganoglu T, et al. Intratympanic methylpredni-solone injections for subjective tinnitus. J Laryngol Otol 2009; 123:1221-1225.
38. She W, Dai Y, Du X, et al. Treatment of subjective tinnitus: a comparative clinical study of intratympanic steroid injections vs. oral carbamazepine. Med Sci Monit 2009; 15:135-139.
39. Itoh A, Sakata E. Treatment of vestibular disorders. Acta Otolaryngol Suppl 1991; 481:617-623.
40. Silverstein H, Isaacson JE, Olds ME, et al. Dexamethasone innerear perfusion for the treatment of Meniere's disease: a prospective, randomized, double-blind, crossovertrial. Am J Otol 1998; 19:196-201.
41. Garduno-Anaya MA, Couthino De Toledo H, Hinojosa-Gonzalez R, et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005; 133:285-294.
42. Boleas-Aguirre MS, Lin FR, Della Santina CC, et al. Longitudinal results with intratympanic dexamethasone in the treatment of Meniere's disease. Otol Neurotol 2008; 29:33-38.
43. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001; 22:18-23.
44. Battista RA. Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005; 132:902-905.
45. Herr BD, Marxo SJ. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005; 132:527-531.
46. Plaza G, Herraiz C. Intratympanic steroids for treatment of sudden hearing loss. Otolaryngol Head Neck Surg 2007; 137:74-78.
47. Haynes DS, O'Malley M, Cohen S, et al. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngo-scope 2007; 117:3-15.
48. Dodson KM, Sismanis A. Intratympanic perfusion for the treatment of tinnitus. Otolaryngol Clin North Am 2004; 37:991-1000.
49. Yang GSY, Son H, Keithley EM, et al. Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss. Am J Otol 2000; 21:499-504.
50. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg 2007; 137:747-752.
51. Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: effect of intra-tympanic dexathethasone injections. Otol Neurotol 2008; 29:1005-1011.
52. Borkholder DA. State-of-the-art mechanisms of intracochlear drug delivery. Curr Opin Otolaryngol Head Neck Surg 2008; 16:472-477.
53. Silverstein H. Useof a newdevice, the microwick, todeliver medication tothe inner ear. Ear Nose Throat J 1999; 78:595-600.
54. Silverstein H, Jackson LE, Rosenberg SI. Silverstein Microwickfortreatment ofinnereardisease. Oper Tech Otolaryngol Head Neck Surg 2001; 12:144-147.
55. Hill SL, Digges EN, Silverstein H. Long-term follow-up after gentamicin application via the Silverstein Micro Wick in the treatment of Meniere's disease. Ear Nose Throat J 2006; 85:494-498.
56. Suryanarayanan R, Srinivasan VR, O'Sullivan G. Transtympanic gentamicin treatment using Silverstein Micro Wick in Meniere's disease patients: long term outcome. J Laryngol Otol 2009; 123:45-49.
57. Van Wijck F, Staecker H, Lefebvre PP. Topical steroids therapy using the Silverstein Microwick in sudden sensorineural hearing loss after failure of conventional treatment. Acta Otolaryngol 2007; 127:1012-1017.
58. Weisskopf P, Hoffer ME, Kopke RD, et al. Microdosegentamicin delivered via the round window microcatheter: a therapeutic option in Meniere's disease. Oper Tech Otolaryngol Head Neck Surg 2001; 12:154-156.
59. De Cicco MJ, Hoffer ME, Kopke RD, et al. Round-window microcatheter administered microdose gentamicin: results from treatment of tinnitus asso-ciated with Meniere's disease. Int Tinnitus J 1998; 4:141-143.
60. Lefebvre PP, Staecker H. Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol 2002; 122:698-702.
61. Plontke S, Lowenheim H, Preyer S, et al. Outcomes research analysis of continuous intratympanic glucocorticoid delivery in patientswith acute severe to profound hearing loss: basis for planning randomized controlled trials. Acta Otolaryngol 2005; 125:830-839.
62. Plontke SK, Lowenheim H, Mertens J, et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of system therapy. Laryngoscope 2009; 119:359-369.
63. Stover T, Paasche G, Lenarz T, et al. Development of a drug delivery device: using the femtosecond laser to modify cochlear implant electrodes. Cochlear Implants Int 2007; 8:38-52.
64. Fiering J, Mescher MJ, Leary Swan EE, et al. Local drug delivery with a self-contained, programmable, microfluidic system. Biomed Microdevices 2009; 11:571-578.
65. Endo T, Nakagawa T, Kita T, et al. Novel strategy for treatment of inner ears using a biodegradable gel. Laryngoscope 2005; 115:2016-2020.
66. Iwai K, Nakagawa T, Endo T, et al. Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel. Laryngoscope 2006; 116:529-533.
67. Lee KY, Nakagawa T, Okano T, et al. Novel therapy for hearing loss:delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel. Otol Neurotol 2007; 28:976-981.
68. Inaoka T, Nakagawa T, Kikkawa YS, et al. Local application of hepatocyte growth factor using gelatin hydrogels attenuates noise-induced hearing loss in guinea pigs. Acta Otolaryngol 2009; 129:453-457.
69. Borden RC, Saunders JE, Berryhill WE, et al. Hyaluronic acid hydrogel sustains the delivery of dexamethasone across the round window membrane. Audiol Neurootol 2010; 16:1-11.
70. Arnold W, Senn P, Hennig M, et al. Novel slow-and fast-type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs. Audiol Neurotol 2005; 10:53-63.
71. Wang X, Dellamary L, Fernandex R, et al. Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach. Audiol Neurotol 2009; 14:393-401.
72. Tamura T, Kita T, Nakagawa T, et al. Drug delivery to thecochlea using PLGA nanoparticles. Laryngoscope 2005; 115:2000-2005.
73. Ge X, Jackson RL, Liu J, et al. Distribution of PLGA nanoparticles in chinchilla cochleae. Otolaryngol Head Neck Surg 2007; 137:619-623.
74. Praetorius M, Brunner C, Lehnert B, et al. Transsynaptic delivery of nano-particles to the central auditory nervous system. Acta Otolaryngol 2007; 127:486-490.
75. Horie RT, Sakamoto T, Nakagawa T, et al. Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic microparticles. Laryngoscope 2010; 120:377-383.
76. Zou J, Saulnier P, Perrier T, et al. Distribution of lipid nanocapsules in different cochlearcell populationsafterround windowmembrane permeation. J Biomed Mater Res B Appl Biomater 2008.
77. Scheper V, Wolf M, Scholl M, et al. Potential novel drug carriersfor inner ear treatment: hyperbranched polylysine and lipid nanocapsules. Nanomedicine 2009; 4:623-635.
78. Roy S, Johnston AH, Newman TA, et al. Cell-specific targeting in the mouse inner ear using nanoparticles conjugated with a neurotrophin-derived peptide ligand: potential too for drug delivery. Int J Pharm 2010; 390:214-224.
79. Shephard RK, Xu J. A multichannel scala tympani electrode array incorporat-ing a drug delivery system for chronic intracochlear infusion. Hear Res 2002; 172:92-98.
80. Paasche G, Gibson P, Averbeck T, et al. Technical report: modification of a cochlear implant electrode for drug delivery to the inner ear. Otol Neurotol 2003; 24:222-227.
81. Paasche G, Bogel L, Leinung M, et al. Substance distribution in a cochlea model using different pump rates for cochlear implant drug delivery electrode prototypes. Hear Res 2006; 212:74-82.
82. Dinh C, Hoang K, Haake S, et al. Biopolymer-released dexamethasone prevents tumor necrosis factor alpha-induced loss of auditory hair cells in vitro: implications toward the development of a drug-eluting cochlear implant electrode array. Otol Neurotol 2008; 29:1012-1019.
83. Richardson RT, Wise AK, Thompson BC, et al. Polypyrole-coated electrodes forthedeliveryofchargeand neurotrophinstocochlearneurons. Biomaterials 2009; 30:2614-2624.
84. Kingma GG, Miller JM, Myers MW. Chronic drug infusion into the scala tympani of the guinea pig cochlea. J Neurosci Methods 1992; 45:127-134.
85. Brown JN, Miller JM, Altschuler RA, et al. Osmotic pump implant for chronic infusion of drugs into the inner ear. Hear Res 1993; 70:167-172.
86. Prieskorn DM, Miller JM. Technical report: chronic and acute intracochlear infusion in rodents. Hear Res 2000; 140:212-215.
87. Takemura K, Komeda M, Yagi M, et al. Direct inner ear infusion of dexa-methasone attenuates noise-induced trauma in guinea pig. Hear Res 2004; 196:58-68.
88. Sendowski I, Abaamrane L, Raffin F, et al. Therapeutic efficacy of intra-cochlear administration of methylprednisolone after acoustic trauma caused by gunshot noise in guinea pig. Hear Res 2006; 221:119-127.
89. Eshraghi AA, Adil E, He J, et al. Local dexamethasone therapy conserves hearing in an animal model of electrode insertion trauma-induced hearing loss. Otol Neurotol 2007; 28:842-849.
90. Agterberg MJ, Versnel H, van Dijk LM, et al. Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs. J Assoc Res Otolaryngol 2009; 10:355-367.
91. Chen Z, Kukawa SG, Mc Kenna MJ, et al. Inner ear drug delivery via a reciprocating perfusion system in the guinea pig. J Control Release 2005; 110:1-19.
92. Sewell WF, Borenstein JT, Chen Z, et al. Development of a microfluidics-based intracochlear drug delivery device. Audiol Neurotol 2009; 14:411-422.